CSL continues stellar performance
Biotechnology and vaccines group CSL has confirmed itself as Australia’s global manufacturing powerhouse with net profit after tax for the first half of the year of $1.86 (US$1.25) billion, up eleven per cent on the previous corresponding period. The half saw dramatic growth in its blood-based products, with R&D investment over more than a decade…